Grifols SA (NASDAQ:GRFS)
| 9.22 Delayed Data As of Jan 27 |  0.00 / 0.00%Today’s Change | 5.71 Today|||52-Week Range 13.34 | +8.47% Year-to-Date |
Latest GRFS News | Press Releases
| New Strong Sell Stocks for January 13th (Revised) Jan 16 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 9.22 |
| Today’s open | 9.18 |
| Day’s range | 9.16 - 9.24 |
| Volume | 8,085 |
| Average volume (3 months) | 1,317,286 |
| Market cap | $2.4B |
Data as of 4:00pm ET, 01/27/2023
Growth & Valuation
| Earnings growth (last year) | -69.23% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | +52.70% |
| Revenue growth (last year) | -4.22% |
| P/E ratio | 84.8 |
| Price/Sales | 1.31 |
| Price/Book | 0.90 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| XENEXenon Pharmaceutical... | -0.53 | -1.39% |
| ---- | ||
| AKROAkero Therapeutics I... | 0.00 | 0.00% |
| ---- |
Data as of 3:59pm ET, 01/27/2023
Financials
| Next reporting date | March 2, 2023 |
| EPS forecast (this quarter) | $0.24 |
| Annual revenue (last year) | $5.8B |
| Annual profit (last year) | $216.1M |
| Net profit margin | 3.71% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Barcelona, Catalonia |
Forecasts
